RxDoctor Payments DataLook up a doctor →

Mark Goodwin, MD

Interventional Cardiology · Naperville, ILNPI 1639125867

Payments from drug & device makers

$282,348in general payments, 2019–2025

Across 488 payments — averaging $578.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$83K
  • Shockwave Medical, Inc$76K
  • Boston Scientific$28K
  • Abbott$22K
  • Medtronic$18K
  • Cordis US CORP.$16K
  • plus $40K from 35 others
$12,028in research payments, 2019–2025

Across 14 payments — averaging $859.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Philips North America LLC$12K
  • Abiomed$503

What the payments were for

  • Consulting fees$46,46038%
  • Speaking & faculty fees$33,75028%
  • Travel & lodging$20,12517%
  • Food & beverage$20,09617%
  • Education$20%
  • Entertainment$6121%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$282,348 in reported general payments places this provider in the 90th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$447,840
Medicare patients
915
Services billed
4,281

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban174$209,584
XareltoRivaroxaban153$169,592
EntrestoSacubitril/Valsartan76$77,091
Repatha SureclickEvolocumab40$46,823
JardianceEmpagliflozin24$30,688
BrilintaTicagrelor16$13,504
VascepaIcosapent Ethyl12$12,830
Metoprolol Succinate729$10,683
ClopidogrelClopidogrel Bisulfate679$7,606
Atorvastatin Calcium653$7,053
Rosuvastatin Calcium445$5,206
Dofetilide15$4,891
Ranolazine ErRanolazine18$4,474
Digoxin16$3,578
Losartan Potassium345$3,248

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$72$209,584174 claims
Johnson & JohnsonXarelto$55$169,592153 claims
NovartisEntresto$323$77,09176 claims
Boehringer IngelheimJardiance$88$30,68824 claims
AstraZenecaBrilinta$44$13,50416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 303 interventional cardiology providers in Illinois.

Other interventional cardiology in Naperville

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →